No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.
Dysregulated JAK2 signaling has been shown to play a significant role in the pathogenesis of myeloproliferative disorders. Recently, our work comparing gene expression signatures of primary mediastinal large B-cell lymphomas (PMLBCL) versus nodal diffuse large B-cell lymphomas revealed a relative increase in JAK2 transcripts in the former, suggesting a role for increased JAK2 signaling in a subset of these tumors. Given the likelihood of increased JAK2 signaling in PMLBCL, we sought to determine whether JAK2 activating mutations were an alternative mechanism for increased JAK2 signaling in untreated PMLBCLs. We performed amplification refractory mutation analysis for the JAK2 (V617F) mutation and bidirectional sequencing for the recently described JAK2 exon 12 mutations on genomic DNA isolated from a well-characterized cohort of PMLBCLs. No evidence of the mutant JAK2 (V617F) allele or JAK2 exon 12 mutations was detected in 31 PMLBCL cases tested. Analysis using cell lines derived from PMLBCLs (n = 1) and from the molecularly similar classic Hodgkin lymphoma (n = 4) also failed to reveal involvement of a mutant JAK2 allele. Taken together, these results suggest that JAK2 signaling in PMLBCLs occurs by mechanisms distinct from JAK2 (V617F) or JAK2 exon 12 activating mutations.
Wu
David
D
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Dutra
Bethany
B
Lindeman
Neal
N
Takahashi
Hidenobu
H
Takeyama
Kunihiko
K
Harris
Nancy L
NL
Pinkus
Geraldine S
GS
Longtine
Janina
J
Shipp
Margaret
M
Kutok
Jeffery L
JL
D005091:Exons; D005787:Gene Frequency; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D016400:Lymphoma, Large-Cell, Immunoblastic / Q000175:diagnosis* / Q000235:genetics*; D008479:Mediastinal Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D020125:Mutation, Missense
C507924:JAK2 protein, human; D053614:Janus Kinase 2
Ann Hematol. 2001;80 Suppl 3:B49-53
11757707
Nature. 1997 Jun 26;387(6636):917-21
9202125
Int J Cancer. 2003 Feb 10;103(4):489-95
12478664
N Engl J Med. 2007 Feb 1;356(5):459-68
17267906
Nature. 1997 Jun 26;387(6636):921-4
9202126
J Leukoc Biol. 1999 Oct;66(4):588-92
10534114
Blood. 2005 Sep 15;106(6):2162-8
15920007
Jpn J Cancer Res. 1999 Sep;90(9):951-6
10551323
Lancet Oncol. 2002 Apr;3(4):229-34
12067685
Blood. 2005 Mar 15;105(6):2535-42
15572583
Am J Surg Pathol. 1989 Sep;13(9):730-9
2788371
Leukemia. 2006 Jan;20(1):157-8
16331280
Genes Chromosomes Cancer. 2001 Apr;30(4):393-401
11241792
Cancer Res. 2000 Feb 1;60(3):549-52
10676635
Nat Genet. 2001 May;28(1):29-35
11326271
Blood. 2003 Dec 1;102(12):3871-9
12933571
Am J Surg Pathol. 1986 Mar;10(3):176-91
3953939
Blood. 2002 Jun 15;99(12):4283-97
12036854
Blood. 2008 Feb 1;111(3):1686-9
17984312
J Clin Invest. 2006 Oct;116(10):2695-706
16906227
J Exp Med. 2003 Sep 15;198(6):851-62
12975453